Bioscience Co. Allegedly Hid Volatility Risks From Investors
By Emilie Ruscoe · April 27, 2026, 4:27 PM EDT
A company purportedly focused on using traditional Chinese medicine to treat conditions including autism spectrum disorder faces a proposed investor class action alleging it downplayed the risk it would be probed...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login